Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) | ...

Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV ...

Merck & Co., Inc. (NYSE:MRK) is included among the Billionaire Ken Fisher’s Top 11 Dividend Stock Picks. Reuters reported on ...

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today shared updates on the company’s oncology pipeline and focused approach to the research and development of ...

Keytruda Patent Expiration Forces Action US industry leader Merck & Co. dominates cancer therapy with the immune checkpoint ...

Merck & Co. will partner with Protillion Biosciences to discover multiple new therapy candidates, through a collaboration ...

In the closing of the recent trading day, Merck (MRK) stood at $113.87, denoting a -1.36% move from the preceding trading day.

Gilead Sciences Inc. and Merck & Co. said an experimental long acting pill combining two HIV medicines had met its primary ...

Merck has dropped autoimmune asset MK-6194 from its pipeline because it "did not confer clinical benefit," a spokesperson told Fierce. (blacklight_trace/iStock/Getty ...

Merck looks like a buy-the-dip at $114.90 with a 3% yield and 12x forward P/E. Click here to read more on the MRK stock.

For patients and doctors, Merck's Keytruda Qlex promises the benefit of convenience and reduced time spent during treatment, all with the same level of efficacy as the original Keytruda. (Angus ...

Pharmaceutical giant Merck is acquiring a Raleigh company whose technology helps poultry producers identify the sex of chicks ...